echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Targeting STING and the inflammasome with $140 million to drive innovative therapies into the clinic

    Targeting STING and the inflammasome with $140 million to drive innovative therapies into the clinic

    • Last Update: 2022-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Ventus Therapeutics announced the completion of a $140 million Series C financing


    Ventus' R&D pipeline targets the inflammasome and DNA sensing pathways of the innate immune system


    Ventus' ReSOLVE platform combines structural biology and protein science expertise with its proprietary computational chemistry capabilities to discover and characterize previously unknown or poorly understood protein surface binding pockets Bound small molecule structures


    ▲Ventus product pipeline (Ventus official website)

    Its lead project VENT-01 is a peripherally restricted small molecule inhibitor targeting NLRP3


    Ventus' third project targets cyclic GMP-AMP synthase (cGAS), a key regulator of the stimulator of interferon genes (STING) pathway


    References:

    References:

    [1] Ventus Therapeutics Closes $140 Million Series C Financing.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.